NCI-H209 [H209] (ATCC® HTB-172)

Organism: Homo sapiens, human  /  Tissue: lung; derived from metastatic site: bone marrow  /  Disease: carcinoma; small cell lung cancer

Organism Homo sapiens, human
Tissue lung; derived from metastatic site: bone marrow
Product Format frozen
Morphology epithelial
Culture Properties aggregates in suspension
Biosafety Level 1
Disease carcinoma; small cell lung cancer
Gender male
Ethnicity Caucasian
Storage Conditions liquid nitrogen vapor phase
Karyotype This is a hyperdiploid human cell line., The modal chromosome number is 49, occurring at 28% with a frequency of higher ploidies of 1.3%. Ten to eleven markers were common to all cells including: der(1)t(1;3)(p22;p21), del(6)(q21), t(8q18q), del(12)(q13), der(14)t(14;?)(q32;?)., All had a single copy per cell. About 6 other markers were found, but they occurred only once in all metaphases karyotyped. Neither HSR nor DM were detected., Structurally normal B group chromosomes were not detected. All C group chromosomes were paired. A single copy of both the X and Y was found in all cells.
Derivation
The NCI-H209 cell line was derived by A.F. Gazdar and associates in 1979 from the bone marrow of a patient with small cell cancer of the lung.
Clinical Data
The bone marrow specimen was taken prior to therapy.
Oncogene pRB + (abnormal, RB1)
Tumorigenic Yes
Effects
Yes, forms transplantable tumors with typical SCLC histology in nude mice
Comments
C-myc DNA sequences are not amplified.
No gross structural DNA abnormalities were detected.
This is a cell line that grows as large aggregates in suspension. Only the aggregates are viable, but no meaningful viability percentage can be measured. The medium will normally contain large amounts of cell debris.

The cells express an aberrant form of RB1 that is not phosphorylated, apparently due to a single point mutation at codon 706 (Cys -> Phe).

The line is a classic SCLC cell line which expresses elevated levels of four biochemical markers (neuron specific enolase, brain isoenzyme of creatine kinase, L-DOPA decarboxylase and bombesin-like immunoreactivity.
The line produces normal amounts of p53 mRNA relative to normal lung.

Complete Growth Medium Iscove's modified Dulbecco's medium, 90%; fetal bovine serum, 10% - OR - RPMI 1640 medium, 90%; fetal bovine serum, 10%
Subculturing
The line should be subcultured by dilution with fresh medium. Alternatively, the clusters may be collected by centrifugation and resuspended in fresh medium.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation
Culture medium, 95%; DMSO, 5%
STR Profile
Amelogenin: X,Y
CSF1PO: 11
D13S317: 11
D16S539: 9,12
D5S818: 12
D7S820: 9
THO1: 7,9
TPOX: 8
vWA: 18,19
Isoenzymes
AK-1, 1
ES-D, 1
G6PD, B
Me-2, 0
PGM1, 1-2
PGM3, 1
Name of Depositor AF Gazdar, JD Minna
References

Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

Kaye FJ, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. PubMed: 2168563

Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760

Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024

Cross References

Nucleotide (GenBank) : A93403 Sequence 1 from Patent WO9741834.

Nucleotide (GenBank) : A93404 Sequence 2 from Patent WO9741834.

Basic Documentation
References

Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

Kaye FJ, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. PubMed: 2168563

Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760

Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024